Advancing Oral Splice-Modulating Small Molecules Toward Clinical Development for Rare Neurodegenerative Diseases
- Overcoming challenges while progressing oral RNA splicing modulators into the clinic
- Optimizing activity and selectivity on multiple targets to achieve the best target profile
- Sharing progress on RTX-317 as ReviR advances its next RNA splicing modulator program toward IND-enabling studies